The China Mail - Who should get paid for nature's sequenced genes?

USD -
AED 3.672504
AFN 66.503991
ALL 80.629676
AMD 365.091035
AOA 917.000367
ARS 1491.937897
AUD 1.417435
AWG 1.80125
AZN 1.70397
BAM 1.691649
BBD 2.00813
BDT 123.418242
BHD 0.375989
BIF 2985.079791
BMD 1
BND 1.277602
BOB 11.849673
BRL 5.083304
BSD 0.997016
BTN 94.875232
BWP 13.457596
BYN 2.968819
BYR 19600
BZD 2.00519
CAD 1.39545
CDF 2262.50392
CHF 0.80949
CLF 0.023206
CLP 913.315746
CNY 6.747604
CNH 6.743285
COP 3142.844787
CRC 453.228387
CUC 1
CUP 26.5
CVE 95.372573
CZK 20.982104
DJF 177.546166
DKK 6.46804
DOP 58.20179
DZD 132.308956
EGP 49.555853
ERN 15
ETB 160.923669
EUR 0.86495
FJD 2.20855
FKP 0.740916
GBP 0.742583
GEL 2.610391
GGP 0.740916
GHS 11.700039
GIP 0.740916
GMD 73.503851
GNF 8756.649224
GTQ 7.607144
GYD 208.588851
HKD 7.84315
HNL 26.723176
HRK 6.518804
HTG 130.363707
HUF 314.060388
IDR 17801
ILS 2.99985
IMP 0.740916
INR 95.210504
IQD 1306.058902
IRR 1375550.000352
ISK 123.340386
JEP 0.740916
JMD 158.335856
JOD 0.70904
JPY 157.80604
KES 129.014401
KGS 87.450384
KHR 4049.647537
KMF 426.00035
KRW 1407.860383
KWD 0.30866
KYD 0.830861
KZT 467.275008
LAK 22510.919863
LBP 89282.792025
LKR 334.420274
LRD 179.959348
LSL 16.197552
LTL 2.95274
LVL 0.60489
LYD 6.341738
MAD 9.29222
MDL 17.337716
MGA 4254.638239
MKD 53.215413
MMK 2099.750695
MNT 3597.347644
MOP 8.056654
MRU 40.080439
MUR 47.070378
MVR 15.450378
MWK 1728.841413
MXN 17.13645
MYR 4.090104
MZN 63.905039
NAD 16.197552
NGN 1364.860377
NIO 36.690741
NOK 9.51237
NPR 151.800372
NZD 1.701115
OMR 0.382693
PAB 0.997016
PEN 3.376465
PGK 4.406003
PHP 60.705038
PKR 276.796523
PLN 3.719205
PYG 5928.296501
QAR 3.644596
RON 4.536304
RSD 101.492021
RUB 81.598409
RWF 1466.072741
SAR 3.755591
SBD 8.065696
SCR 14.449077
SDG 600.503676
SEK 9.480804
SGD 1.278038
SLE 24.603667
SOS 569.822255
SRD 37.866504
STD 20697.981008
STN 21.191022
SVC 8.723782
SZL 16.194265
THB 33.050369
TJS 9.197509
TMT 3.51
TND 2.929032
TRY 47.697504
TTD 6.757774
TWD 32.250604
TZS 2639.622886
UAH 44.653894
UGX 3714.050945
UYU 40.133201
UZS 11924.058297
VES 755.762404
VND 26204.5
VUV 119.414824
WST 2.733661
XAF 567.363231
XAG 0.015731
XAU 0.00023
XCD 2.70255
XCG 1.796912
XDR 0.705618
XOF 567.363231
XPF 103.152705
YER 238.403589
ZAR 16.14632
ZMK 9001.203584
ZMW 18.818492
ZWL 321.999592
  • CMSC

    0.0240

    21.744

    +0.11%

  • BCC

    2.3400

    86.6

    +2.7%

  • BCE

    -0.0200

    22.75

    -0.09%

  • GSK

    0.7900

    52.96

    +1.49%

  • BP

    -0.6000

    41.63

    -1.44%

  • RBGPF

    0.7600

    70.5

    +1.08%

  • BTI

    0.6000

    59.33

    +1.01%

  • RIO

    1.4500

    101.1

    +1.43%

  • AZN

    1.4100

    161.42

    +0.87%

  • NGG

    0.4700

    80.88

    +0.58%

  • CMSD

    -0.1600

    21.82

    -0.73%

  • JRI

    0.1500

    12.81

    +1.17%

  • VOD

    0.1900

    16.19

    +1.17%

  • RELX

    0.0485

    35.52

    +0.14%

  • RYCEF

    0.2300

    20.85

    +1.1%

Who should get paid for nature's sequenced genes?
Who should get paid for nature's sequenced genes? / Photo: © AFP/File

Who should get paid for nature's sequenced genes?

Much of the vanilla that flavors our ice cream today is artificial, derived from the genetic signature of a plant that hundreds of years ago was known only to an Indigenous Mexican tribe.

Text size:

The plant's sequenced genomic information, available on public databases, was used as the basis for a synthetic flavoring that today competes with vanilla grown in several countries, mainly by small-scale farmers.

Few, if any, benefits of the lucrative scientific advance have trickled down to the communities that gave us vanilla in the first place.

"Wild genetic resources and pharmaceuticals ... are a multi-multi-billion dollar businesses. They clearly are profitable... that's not in dispute," Charles Barber of the World Resources Institute think tank told AFP.

"A great deal of really valuable information has fed into the system from research and utilization of wild genetic resources. And there is no mechanism currently to compensate the people where this information is coming from" in the form of digitally sequenced data, he added.

Much of the information comes from poor countries.

Fair sharing of the gains derived from digitally-stored genetic sequencing data has been a headache for negotiators at the COP16 biodiversity summit into its second week in Cali, Colombia.

At the last conference, in Montreal in 2022, 196 country parties to the UN's Convention on Biological Diversity (CBD) agreed to create a benefit-sharing mechanism for the use of digital sequence information (DSI).

Two years later, they still need to resolve such basic questions as who pays, how much, into which fund, and to whom does the money go?

- 'Cheap and very fast' -

The issue is a complex one.

There is little debate that genetic data-sharing on mostly free-access platforms is crucial for human advancement through medicine and vaccine development, for example.

But how to quantify the value of the sequenced information itself? And should the first people to discover a plant's particular usefulness be compensated?

"Sequencing technology has become so advanced that you can go with a... handheld device a little bit bigger than a cell phone and you can literally sequence a genome in an hour or two and upload it as you sequence it," Pierre du Plessis, a DSI expert and former negotiator for African countries at the CBD told AFP.

These gene sequences are then uploaded to databases which artificial intelligence can mine for potential leads for product development.

DSI is worth an estimated hundreds of billions of dollars a year. And there is a lot of it out there.

"Once the sequence is put into a public database, generally, no benefit-sharing obligations apply," Nithin Ramakrishnan, a researcher with the Third World Network, an advocacy NGO for developing countries, told AFP in Cali.

"Like when the sandalwood sequence information is available in the database whether India wants to share its sandalwood... with a cosmetic company or not, doesn't matter.

- Mandatory -

A point of contention in Cali is a demand from developing countries that payment for DSI use be mandatory, perhaps through a one-percent levy on profits from drugs, cosmetics or other products.

They also want guarantees of non-monetary benefits such as access to vaccines produced from genetic information sequenced from viruses and other pathogens.

"We want real understanding, sector-specific understanding of what non-monetary benefits will be shared and we want the system to be obligatory -- the users should have some form of obligation to share benefits," said Ramakrishnan.

Another sticking point is access for Indigenous people and local communities to DSI funds.

Developing countries want the information on genetic databases to be traceable and "answerable to governments" of the countries where it comes from, said Ramakrishnan.

But rich nations and many researchers oppose such a model which they fear will be too onerous, potentially putting the brakes on scientific pursuits that could benefit all humankind.

With such divergent points of view, observers are doubtful the Cali COP will emerge with any firm decisions on the outstanding questions by closing time on Friday.

The World Wildlife Fund has said "many more rounds of negotiations appear necessary" on DSI.

Added Barber: "I think it's not going to all get solved here."

Y.Su--ThChM